BioinformaticsbioRxivPreprint
Utilizing proteomics and phosphoproteomics to predict ex vivo drug sensitivity across genetically diverse AML patients
Sara J.C. Gosline, Cristina E. Tognon, Michael D. Nestor…·Karin Rodland
The paper predicts ex vivo drug sensitivity in AML patients using proteomic and phosphoproteomic signatures, showing better accuracy than mutation or mRNA-based signatures.
DOI 10.1101/2021.06.04.447154